Researchers from the University of Texas, together with pharmacists from MedCara Pharmaceuticals, have developed a nasal spray containing testosterone to treat anxiety disorders. The drug has already received its second patent in the U.S. and first in Europe, making it the first licensed testosterone-based anxiety disorder treatment.
As the scientists explained, the need to develop the testosterone spray arose from a study that confirmed the role of testosterone in the etiology of anxiety disorders. It was shown that with the onset of puberty, girls significantly increase the degree of exposure to anxiety disorders compared to boys.
At the same time, scientists have noted that the level of testosterone in girls is equal to only a tenth of the testosterone in boys. So the researchers came to the assumption that it is testosterone that protects boys from anxiety disorders. This assumption led scientists to develop a special spray based on testosterone.
While testosterone is not usually prescribed as a therapeutic agent for patients with anxiety disorders, scientists see great potential in the drug they developed: in combination with low doses of standard benzodiazepines (such as alprazolam and clonazepam) testosterone spray can help reduce the intensity of symptoms in anxiety disorders such as post-traumatic stress disorder and obsessive-compulsive disorder.
In addition, the new spray may also help people with hypogonadism, lowered testosterone levels and libido. Compared to other treatments for these ailments (drops, creams and gels for external use and injections), the testosterone-based nasal spray works much faster.
The spray has been licensed in the U.S. and Europe, and is awaiting approval in China. Thus, the product may soon become available almost all over the world.